In particular, for patients with hematopoietic and lymphoid tumors, determining the levels of RND1 in tumor tissues would help to evaluate their response to inhibitors of growth factor receptors (IGFR1, EGFR, c-met and multiple receptor tyrosine kinase), MAPK pathway, tyrosine kinases (Abl and Alk), and γ secretase. Here, ALK is linked to neoplasm.